TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma – I-Mab | Pioneering the Next Generation of Immuno-Oncology

Who We Are
A global innovative biotech company
Value Creation
Laser-focused on delivering innovative therapies to patients in need
Leadership Team
A world-class global leadership team
People and Culture
People are the cornerstone of our success
Commitment to ESG
Committed to the highest environmental, social and governance standard